









Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on July 2023

Classification of products:

Status	Description
 GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 RED	Red-Hospital initiation and continuation only
 GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 PURPLE	To be supplied from the appropriate commissioned provider.
 NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
Nil this month				
2) New Requests				
Teduglutide	RED			As per NICE guidance (TA804) NHS England is the responsible commissioner and HUTH is an NHS England commissioned provider
Tenecteplase	RED			For Acute ischaemic stroke
Ibuprofen IV	RED			Approved for acute post operative pain in paediatrics only.
3) New formulations & extensions to use				

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Nil this month				
4) Products considered by NICE				
TA882: Voclosporin with mycophenolate mofetil for treating lupus nephritis	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA885: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA886: Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA887: Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA888: Risankizumab for previously treated moderately to severely active Crohn's disease	RED			The formulary will reflect the TAG – ICS is the responsible commissioner.
TA890: Difelikefalin for treating pruritus in people having haemodialysis	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA891: Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA905: Upadacitinib for previously treated moderately to severely active Crohn's disease (30 day TA)	RED			The formulary will reflect the TAG – ICS is the responsible commissioner.
5) Appeals against earlier decisions by the APC				
None				

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
6) Miscellaneous formulary decisions by the APC				
Duraphat Toothpaste	RED			Remain RED and update with caveats
Estrodiol vaginal tablets	GREEN			Update NetFormulary with generic and comment on brands
Procainamide				Remove from formulary as product no longer available in UK
Ketamine oral	RED			For use by pain team (existing patients only) and palliative care team
Lisdexamfetamine	RED			Update NetFormulary with generic name and remove brands
Capsaisin cream	GREEN			Patches to be removed from NetFormulary and 0.075% strength to be added
Sunsense Ultra				Product no longer available- updated with Uvistat as replacement (ACBS criteria only)
Tranexamic acid mouthwash	RED			Unlicensed preparation for use by oncology/haematology/OMFS

The following guidelines were presented to and approved at the July 2023 meeting of the APC:

- Nil

The following Green+ drug information leaflets were presented to and approved at the July 2023 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the July 2023 meeting of the APC:

- Nil

Other documents presented to and approved at the July 2023 meeting of the APC:

- Nil